Billiau An D, Roskams Tania, Van Damme-Lombaerts Rita, Matthys Patrick, Wouters Carine
Pediatric Rheumatology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.
Blood. 2005 Feb 15;105(4):1648-51. doi: 10.1182/blood-2004-08-2997. Epub 2004 Oct 5.
Macrophage activation syndrome (MAS) is a rare and potentially fatal disorder, thought to result from uncontrolled activation and proliferation of T cells and excessive activation of macrophages. The term MAS designates a clinicopathologic entity that occurs in different hemophagocytic syndromes (HSs). Primary hemophagocytic lymphohistiocytosis (HLH) is recognized to have an immunogenetic basis, but in the secondary HS (also referred to as secondary HLH), the cause is unknown. The pathogenesis of the accelerated disease phase typical of MAS remains incompletely understood. This report describes the immunohistochemical findings on liver tissues from 5 children, each of whom presented with MAS in the context of a different type of HS. The data provide direct evidence for the involvement of activated CD8(+) lymphocytes through the production of interferon-gamma and of macrophages through hemophagocytosis and production of interleukin 6 and tumor necrosis factor-alpha, and underscore the view that MAS in different HSs share a common effector pathway.
巨噬细胞活化综合征(MAS)是一种罕见且可能致命的疾病,被认为是由T细胞的失控激活和增殖以及巨噬细胞的过度激活所致。术语MAS指的是一种发生于不同噬血细胞综合征(HSs)的临床病理实体。原发性噬血细胞性淋巴组织细胞增生症(HLH)被认为有免疫遗传学基础,但在继发性HS(也称为继发性HLH)中,病因尚不清楚。MAS典型的疾病加速期的发病机制仍未完全明了。本报告描述了5名儿童肝脏组织的免疫组化结果,每名儿童均在不同类型的HS背景下出现MAS。这些数据为活化的CD8(+)淋巴细胞通过产生干扰素-γ参与其中以及巨噬细胞通过噬血细胞作用和产生白细胞介素6和肿瘤坏死因子-α参与其中提供了直接证据,并强调了不同HSs中的MAS共享一条共同效应途径的观点。